Our recent study of human lung cancers showed that macrophages and plasma cells can also predominate in tumors (22), and it will be important to test EZH2 inhibition in the context of diverse tumor immune microenvironments moving forward. The gene discussed is EZH2; the disease is lung carcinoma.